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Abstract
Goals—To understand patients’ perceptions of factors which facilitate and hinder adherence in 
order to inform adherence-enhancing interventions.
Background—Adherence to antiviral therapy for hepatitis C viral infection is critical to 
achieving a sustained virological response (SVR). However, persistence with and adherence to 
antiviral regimens can pose challenges for patients that interfere with SVR.
Study—A qualitative analysis of 21 semi-structured patient interviews using open-ended 
questions and specific follow-up probes was conducted. Interviews were audio-recorded, 
transcribed, and content-analyzed iteratively to determine frequent and salient themes.
Results—Three broad themes emerged: 1) missing doses and dose-timing errors; 2) facilitators 
of adherence; and 3) barriers to adherence. Open-ended questioning revealed few dose-timing 
deviations, but more specific probes uncovered several more occurrences of delays in dosing. 
Facilitators of adherence fell into two broad categories: (a) patient knowledge and motivation and 
(b) practical behavioral strategies and routines. Facilitators were noted post hoc to be consistent 
with the Information-Motivation-Behavioral Skills Model of Adherence. Barriers to adherence 
involved changes in daily routine, being preoccupied with family or work responsibilities, and 
sleeping through dosing times. A few patients reported skipping doses due to side effects. Patients 
with previous HCV treatment experience may have fewer dose-timing errors. Finally, a high level 
of anxiety amongst some patients was discovered regarding dosing errors. Emotional and 
informational support from clinical and research staff was key to assuaging patient fears.
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Conclusions—This qualitative study improves our understanding of patients’ perspectives 
regarding adhering to hepatitis C treatment and can lead to the development of adherence-
enhancing interventions.
INTRODUCTION
Adherence to antiviral treatment regimens for chronic hepatitis C viral (HCV) infection is 
imperative to successful eradication of the virus (1). Previous research has shown that 
patients may discontinue HCV treatment prematurely due to patient-driven issues such as 
noncompliance, lost to follow-up, patient preference, or the inability to tolerate 
uncomfortable, but not life-threatening treatment side effects (2). Patient-driven treatment 
discontinuations is often referred to as “nonpersistence” in the broader adherence literature, 
and refers to the patient’s ability to stay on the treatment for the fully prescribed regimen (3, 
4). In contrast, “medication adherence” refers to the patients’ ability to conform to the 
regimen’s timing, dosage, and dosing frequency prescribed by the doctor (3, 4). Patients 
undergoing HCV treatment can have issues with both medication persistence (i.e., persisting 
on the full course of antiviral therapy) and medication adherence, (i.e., taking all of the 
medications exactly as prescribed without missed doses). Previous research, including that 
conducted by our group, demonstrates that HCV patients can have difficulty taking their 
medications as prescribed, nonadherence worsens over the course of treatment, and is linked 
to lower virological response and sustained virological response (SVR) (1, 2, 5, 6). Notably, 
patients have a more difficult time dosing oral antiviral medications, such as ribavirin 
(RBV), compared to dosing once a week self-injection of pegylated interferon (PegIFN). 
This observation will be of great clinical importance as many countries begin to phase out 
the use of PegIFN antiviral regimens in the coming years, which may improve persistence 
on HCV treatment. However, adherence to dosing of oral medications may still be a 
clinically important issue to understand from the perspective of the patient, so clinicians 
know what questions to ask and how to discuss adherence-enhancing tactics with their 
patients.
While previous quantitative studies describe the pattern and prevalence of medication 
nonadherence during HCV treatment (2, 5, 6), exactly how and why patients do or do not 
take their HCV medications as prescribed remains unclear. Although previous adherence 
research with medication regimens for other patient populations has been cited, there may be 
more dissimilarities than commonalities among these regimens and populations (7, 8). Thus, 
caution needs to be applied when generalizing other adherence findings to the HCV patient 
population and regimen, until more systemic research is conducted in this rather 
unprecedented patient population. Understanding the unique patient perceptions and 
experiences of what factors facilitate or sabotage adherence to HCV treatment will improve 
our understanding of these nuances, and inform clinical practice and interventions to help 
patients optimize treatment outcomes. In particular, understanding patients’ nonadherence to 
taking oral medications will become increasingly salient in the years to come.
Qualitative methods using in-depth, open-ended patient interviews or focus groups are 
particularly useful to study under-developed research areas, and have recently been applied 
to the field of HCV, although not specifically to study patient adherence to HCV treatment 
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(9–12). In this study, we applied qualitative research methods, which can either generate 
hypotheses to test in larger quantitative studies or inform intervention development and 
practice, (13) to understand patients’ perceptions of the most salient facilitators and barriers 
to adhering to antiviral treatment regimens for HCV. These data were obtained from a larger 
parent study, a needs assessment of patient experiences during HCV treatment to inform 
interventions to optimize adherence and persistence with antiviral HCV regimens.
MATERIALS AND METHODS
Participants and Setting
Eligible participants were adults 18 years of age or older, diagnosed with HCV genotypes 1, 
2, or 3, and either undergoing or within 4 weeks of completing antiviral therapy, at a large 
tertiary care medical center in the US. We purposively enrolled patients who were in the 
early and late phases of various treatment regimens to capture the wide spectrum of 
heterogeneous experiences that occur across the span of HCV treatment. Participants were 
recruited from two settings: (1) an outpatient liver clinic where patients engaged in standard 
of care biotherapy with PegIFN+RBV therapy; or (2) a clinical research center at the 
hospital where patients were participants in Phase II pharmaceutical trials to evaluate 
combining direct acting antivirals (DAAs) with PegIFN+RBV which were not FDA-
approved at the time of data collection in 2011. Patients on standard PegIFN+RBV dosed a 
total of 5–6 RBV pills twice a day and injected weekly PegIFN. The clinical trial 
participants were involved in trials of triple or quadruple therapy which included PegIFN, 5–
6 RBV pills dosed twice a day, and a once a day dosed DAA (e.g., NS3 or NS5 protease 
inhibitors, polymerase inhibitors, and protease inhibitor boosters). Therefore, all regimens 
required dosing 6–8 pills twice a day plus weekly interferon injections. The only difference 
between regimens was the dosing of an additional DAA once a day among patients in the 
clinical trials. All dosing regimens had a 12-hour dosing window; none required dosing 
every 8 hours. Only one regimen required one patient to dose an experimental pill with food. 
Therefore, in most ways the regimens were very similar preventing comparison of 
differences in pill burden. Thirty consecutive patients were screened for eligibility. Nine 
patients were not enrolled in the study: 3 did not meet inclusion criteria, 2 declined to 
participate, and 4 were missed in clinic. The final sample of 21 patients participated in 
individual, single-session, semi-structured interviews from January through May 2011. This 
study was approved by the UNC Biomedical IRB. All patients gave written informed 
consent and were compensated $20 for their participation.
Study Design and Interview Guide Development
At routine medical or research visits, hepatologists introduced the study to potential 
participants and interested patients were recruited for the study by the coordinator.
The overarching goal of the interviews was to gather qualitative information about patient 
experiences with 1) undergoing antiviral treatment, including treatment-related side effects, 
and psychological and behavioral coping with such side effects, and 2) medication 
adherence, by specifically querying about facilitators and barriers. Based on clinical 
experience, including knowledge of common treatment-related side effects and a review of 
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the HCV treatment and broader adherence literatures, two investigators (D.M.E., C.E.G.) 
developed the interview guide (Table 1). Each interview, conducted by one of two 
interviewers (J.E.B., D.M.E.) lasted about 45 minutes (range 30–90). Initial open-ended 
questions were followed by closed-ended prompts to first allow unanticipated themes to 
arise and then to obtain information about all topics hypothesized to be possibly relevant. 
During the data collection period, study interviewers revised the interview guide to probe 
more about dose-timing deviations based on initial interviews.
Data Collection
Interviews were audio-recorded and transcribed by an external transcriptionist. One author 
(J.E.B.) reviewed all 21 transcriptions for accuracy. At the end of each interview, 
participants completed a brief 15-item self-administered demographic survey. We obtained 
sociodemographic and clinical data such as HCV genotype and evidence of cirrhosis from 
electronic medical records.
Data Analysis
Data were analyzed using a thematic content approach to identify themes relevant to the 
study aims and the relationship among those themes (14). Two coders (D.M.E. and J.E.B. 
who also conducted the study interviews) independently reviewed all transcripts, recording 
preliminary themes based on the major topical headings specified in the interview guide. 
Each also incorporated additional themes pertinent to the study aims that emerged from the 
interview data. Participants’ utterances regarding adherence were generally elicited during 
sections 6 and 7 of the Interview Guide (Table 1) during which the interviewee specifically 
inquired about the process of taking HCV medications; however some utterances related to 
adherence were captured during other sections of the interview. After independently 
reviewing all transcripts, they compared each theme and their associated representative texts 
and came to consensus to develop a codebook with definitions and representative text. The 
two coders then trained a third coder (J.V.) who reviewed all transcripts independently and 
marked appropriate text relating to the themes in the codebook using ATLAS.ti 6.2 
qualitative analysis software, refining the codebook when necessary. The two initial coders 
(D.M.E and J.E.B) jointly reviewed the revised themes and coded text for accuracy and 
further refined the codebook based on review and discussion of coded text, and, with a 
fourth coder (CAG), finalized the coding in ATLAS.ti. Key themes were extracted and 
representative quotes were selected from the final coded data and codebook. We linked each 
utterance to gender, history of depression, cirrhosis status, treatment experience, and 
whether a participant was undergoing treatment via standard of care (SC) or engaged in a 
clinical trial (CT) to determine any group differences. Descriptive statistics were analyzed in 
SPSS v20 (Chicago, IL).
RESULTS
Three broad themes emerged from the final analysis: 1) Missing Doses and Dose-Timing 
Errors; 2) Facilitators of Adherence; and 3) Barriers to Adherence.
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Baseline patient demographic and clinical characteristics are shown in Table 2. The age of 
participants ranged from 33 to 64 (mean=51; SD=8.84). The majority of patients (n=16, 
76%) were infected with genotype 1, followed by genotype 3 (n=3, 14%), and genotype 2 
(n=1, 5%) and genotype 4 (n=1, 5%). Evidence of cirrhosis based on biopsy, fibrosure test 
or physician documentation was documented in 9 cases (43%). Nineteen patients were 
currently undergoing antiviral therapy and two were four weeks post-treatment at the time of 
the interview. We purposively sampled from all weeks during treatment to obtain a wide 
perspective, such that time on treatment ranged from 4 to 40 weeks (mean=17; SD=11.6). 
Eleven patients (52%) were receiving standard of care (SC) dual PegIFN/RBV therapy, 
while 10 Clinical Trial (CT) patients (48%) were participating in clinical trial protocols, all 
of which included PegIFN/RBV in combination with another direct-acting antiviral(s).
Taking Doses “As Soon As”: Missing Doses and Dose-Timing Deviations
When participants were asked in an open-ended manner to describe the process of taking 
their medications, only a few (n=3) reported missing any doses. However, when probed 
further about dose-timing errors or reasons for delaying medication-taking, 11 out of 21 
participants subsequently described deviations in the timing of their doses, i.e., taking them 
later than intended, missing them, or doubling up on doses once they realized they had 
missed a previous dose. The following interchange exemplifies how information about dose 
timing was elicited after the participant initially seemed to be adherent:
Interviewer: So, talk to me a little bit about the process of taking both your medicines, the 
shot and then the pills.
Participant: It hasn’t been any problem for me. I give my own shots and that’s a piece of 
cake.
Interviewer: What day or nights have you done it?
Participant: I think it’s every Thursday night.
Interviewer: So, you took a shot last night?
Participant: No, I couldn’t do it - - you know, so I’ll do it tonight. If I don’t do it Thursday 
night I do it Friday night.
Most deviations in dose timing involved participants taking their doses later than they 
intended, but as soon as possible once they remembered or gained access to their 
medications. One woman said that she might miss it if she got busy, but “as soon as I came 
home, I’d take it. I’ve never been one to miss doses of anything.” Similarly, participants 
reported taking medications “as soon as” they came home after being out to dinner or “as 
soon as” they woke up after falling asleep prematurely. Some participants generally did not 
express concern about taking their oral medications a few hours later because the dosing 
requirement gave a 12-hour window. One woman said, “So, my medication is like one day I 
may take it at 9:30; one day I may take it at noon and so, you know, there’s a lot of leeway 
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around that, the time I took it;” another participant said that missing a dose “wasn’t the end 
of the world.” No perceptible group differences in dose-timing errors occurred between SC 
and CT patients, with both mentioning missing or accidentally delaying doses. However, a 
perceptible difference was found for patients who were previously naïve or experienced with 
HCV treatment. Of 15 patients previously naïve to treatment, 9 (60%) mentioned dose-
timing errors, while only 2 out of 6 (33%) treatment experienced patients mentioned dose-
timing errors. This suggests that prior experience with HCV treatment may be associated 
with fewer dose-timing errors and greater adherence.
Facilitators of Medication Adherence
Patients provided many insights into factors that aided them in taking their medications as 
prescribed. These factors generally fell into two broad categories: those having an impact on 
their motivation or commitment to adhere and behavioral strategies to aid in remembering to 
take medications.
Sources of Motivation—Participants discussed different phenomena they used to 
motivate themselves to take their medications. These phenomena included knowledge or 
information, committing to an external source (e.g., HCV provider/research coordinator or 
research trial), and cognitive (internal locus of control, optimistic thinking) and emotional 
factors (e.g., fear/anxiety). Knowledge or information that antiviral treatment could cure 
them of hepatitis C was a necessary and strong motivator for over half of the participants. 
They used many statements to reflect that simply having information and knowing that 
treatment was effective helped them to take their medications. Several examples include: “I 
know I need to take them,” “Knowing I’m getting better,” “Just to know that this is the 
procedure to get well,” “Just knowing that I need to take ‘em. And, you know, that if I don’t 
that it’s not gonna work.”
Eleven participants described forms of ‘social motivation’ by talking about making a 
commitment and wishing to comply with an external source, as a strong motivator of 
adherence. Several CT participants described committing to a clinical trial as motivation; 
one man said “I was talking about being in the study too ‘cause it keeps you focused and 
this is something you’ve committed to” another man indicated, “This trial means a lot, you 
know. I don’t want to jeopardize the trial in any way.” Six patients, both SC and CT, 
described a commitment to their medical providers’ advice (i.e., doctor, nurse practitioner, 
or research study coordinator); as one woman said, “Hey, you want to get well you better 
listen to the doctor.” Another participant reported adhering to treatment because he did not 
want to “mess up this opportunity”. One man described in detail how trust in his provider 
and commitment to the Alcoholics Anonymous (AA) program motivated him during HCV 
treatment:
“That’s what [doctors] do for a living, you know. If I didn’t trust the doctor when 
this crap started… I know where to go get some valiums, OK? You can go get what 
you want if you’ve got some cash money. And I want a couple blues. And I’m in 
this A.A. program. They said ‘don’t do that.’ They said ‘don’t be your own doctor. 
You tried that shit all your life and it didn’t work.’ So I don’t do that at all. And I 
don’t try to con the doctor out of it either, you know?”
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Many participants talked about their personal motivations to adhere which seemed to 
involve both their belief systems (cognitions, schemas, self-statements) as well as emotional 
states (e.g., anxiety) that appeared to be catalysts related to adherence. They described 
actively shoring up internal sources of personal motivation, through a sense of internal locus 
of control to help them adhere to treatment although the mechanisms for this varied by 
individual. Notably, patients without cirrhosis (7 out of 12; 58%) had a higher proportion of 
utterances implying an internal sense of control compared to patients with cirrhosis (2 out of 
9; 22%). Other participants described a heightened sense of commitment to treatment driven 
by anxiety, as one man said of his treatment, “I’m kind of uptight about it.” Other 
participants said “I’m really persistent when I get myself in that frame of mind to start 
treatment…. I’m like a rabid dog when it comes to taking the treatment when I get myself 
ready for it”, and “You just “rah” all the way through it. Try to get yourself psyched.” 
Sometimes, however, the internal locus of control and sense of responsibility led to 
heightened anxiety levels, particularly if a participant missed his/her medication: “Because 
getting off schedule really, when I get off schedule ‘cause I have one time, I got very scared 
and in order for my disease to go away I have to really stay on schedule and do as I’m 
told.” One patient summed up motivation as being a dually stemming from anxiety and 
external locus of control: “When I get off schedule cause I have one time, I got very scared 
and in order for my disease to go away, I have to really stay on schedule and do as I’m 
told.”
Several participants described using helpful cognitive self-statements to motivate themselves 
for treatment; the language they used in such messages seemed almost aphoristic. Examples 
of such sayings include “If you’re going to take them, take them right;” “I’ve got to take it. 
I’ve got to take it;” “Let’s go get it done;” “I made a decision I’m going to do this and I’m 
going to do this”; “If you want to get better, you’ve got to take it;” and “Why bother doing 
this if I’m not gonna do it?”
Other participants said that future-oriented thinking and contemplating the positive 
consequences of curative treatment was motivating. One man said he was motivated by 
“Knowing that I want to be better. Knowing that I want this stuff away from me. I feel like 
I’ve got a lot more to live for, you know.” Another described reassuring himself that 
treatment would be worthwhile when his disease was cured:
“As soon as I’m off this stuff, you know, whenever the treatment runs out and 
we’re done, then these effects are going to go away. And then if all goes well then 
the virus is gone. And that’s going to, in the long run after a while, make you feel 
even better. So, that’s what you’ve got to focus on, you know, is you might suffer 
now but you’re gonna feel a lot better later.”
With the exception of social motivation related to an external commitment to a clinical trial, 
no other differences between SC and CT participants were noted. Patients without cirrhosis 
made more utterances reflecting an internal locus of control (i.e., I can control life events 
through my own behaviors/actions) compared to cirrhotic patients. SC and CT patients both 
perceived a similar sense of anxiety regarding missed or delayed doses, and both expressed a 
sense of external commitment to HCV treatment personnel: the treating nurse practitioner 
for SC patients and the “doctor” and study research coordinator for CT participants.
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Behavioral Strategies—Participants listed a wide range of specific behavioral strategies 
they used to help them remember or manage taking their medications, which did not differ 
between SC and CT patients. Some individuals devised ways to organize their routine or 
lifestyle to incorporate dosing into their daily activities, some described very specific tools 
or cues used to remember doses, and others talked about strategies they developed 
preemptively to manage taking their medications in the event of a deviation from their 
normal routine, such as travel away from home.
The most frequently mentioned behavioral facilitators were the use of routinized schedules, 
mentioned by all but two participants. Many such routines hinged on mealtime since the oral 
medications were often paired with food to increase absorption or counteract nausea. As one 
participant described, “I’ll take my trial drug after breakfast before work. I’ll take three 
Ribavirin at the same time and I take all my other medications at the same time too every 
morning. Like I said, that way I won’t forget any. Then I’ll take three more Ribavirin after 
lunch, after I’ve had lunch. And then the Peg, I take it on Friday evenings about 8:00, about 
an hour or two before bed.” Participants also said they contoured their dosing routine 
around when they expected their side effects to be worst. One man took his pills just before 
bed: “They say if the side effects are gonna be there, they’re gonna be the first so you want 
to sleep through the first, the worst part of it.” Several said they scheduled their injection for 
Friday evening so that side effects would happen over the weekend rather than during the 
week; as one man said, “I have picked Friday nights to do them cause that way I know that 
I’m gonna be feeling the worst over the next day or two after I take the shot. So, the 
weekends are usually a little freer for me to lay around and be like ‘ehh,’ you know, ‘I’m 
just not feeling well.’ If you need to get something done during the week, then you’re going 
to be able to get something done.”
Three participants spoke of key elements or rituals that were personally important to self-
administering the medication. One CT patient described in detail all the steps of her ritual: 
“I would wake up at 6:00, get my spoon of peanut butter and then I’d get all my medications 
together right there and separate them out, take my pills and I’d take my shot and then I’d 
drink my water.” A SC patient said that it was important to take his shot alone: “It was just 
one of those things. I didn’t mind taking the shots or people knowing I was taking the shots. 
I just didn’t want somebody watching me take the shots. I don’t know.” Another said she 
always sat down in a “certain spot” to do her injection.
A few participants said they had to plan ahead and make adjustments to find a schedule that 
worked best for their lifestyle. As one woman said, “For me I’ve just had to juggle to decide 
what’s best for me. It seemed like if I took really early, mid-day, I was feelin’ punk. But if I 
waited, I didn’t feel punk until it was just about time for bed and I could sleep through it.” 
Some described a collaborative relationship with their provider and spoke of being given 
flexibility from the provider in dosing to select a routine that worked best for them. One 
participant described, “You can tweak around with your timing as long as the doctor knows 
you’re doing it and possibly how many pills you’re taking in the morning versus how many 
pills you’re taking at night or maybe even, you know, there’s a possibility you can take them 
all at once.”
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Four participants described specific strategies they used to reduce the unpleasantness of 
treatment or its side effects. One woman described in detail several pieces of her routine 
designed to make taking the shot more tolerable: “And then the injection I take on Friday 
night at 6:00 and I take it at about 15 minutes before I inject it and let it warm up a little bit. 
And I usually count to seven slow so it won’t go in too fast. ‘Cause I think if you push it fast, 
it burns. And then I like to do mine slow. Then I sit there and rub it…” Another participant 
said he took Tylenol about an hour before the injection. Another said he would try to distract 
himself from the injection’s unpleasant side effects by working, reading a book, or watching 
television. Still another described eating something sweet (“…one or two Skittles, you know, 
a piece of chocolate, whatever…”) to counteract the bitter-tasting pills.
Participants employed other behavioral strategies to assist them in the task of remembering 
to take their medications. For example, one woman said she left her pill box out in her office 
as a cue to remember to take her pills at work, and another described a system he had 
developed of moving the pill bottle from one side of a drawer to another to remember 
whether he had taken them. Seven participants discussed using pill boxes to help them 
remember. Two participants wrote themselves notes; as one described, “Yeah, and if you 
want to do something, write notes. Write notes. I’ve been doing that for a long time anyway, 
you know, cause I’m a type A and I have 15 things going and two jobs and 15 other things to 
do. And if I don’t make notes, it doesn’t get done, you know.” One man relied on his wife to 
remind him to take his pills; as he put it: “She’s ‘take your pills. Take your pills.’” Another 
said he set an alarm on his phone as a cue to dose.
Specific strategies that helped participants who experienced a change in routine, like being 
away from home unpredictably, were described. For example, one participant kept 
medication doses in both his and his wife’s car.
Soliciting emotional and informational support from the doctors, nurse practitioner or 
research coordinators was another behavioral coping strategy employed when patients 
missed or had a delay in dosing. SC participants described their relationship with the treating 
nurse practitioner while the CT patients relied on the study coordinators for emotional and 
tangible support. One CT participant related that she was reassured by the study coordinator 
that if she does experience a deviation in dosing, she should “just call [the coordinator] and 
she’ll put me back on track.” One SC participant described: :
“I had just fallen asleep. And then I had called (nurse practitioner) on Monday and 
she said it was OK, go ahead and take it Monday.”
Another CT participant related, “Yesterday I had to call [my coordinator] and ask her, 
yesterday was a very heavy day. And like I said, I normally eat my lunch and then take my 
three Ribavirin after lunch. I couldn’t remember if I took the Ribavirin or not. So, I called 
her and I said ‘Look, I’ve got about 15 left.’ She said ‘Look. Just don’t take anything till you 
get here and we’ll just go from there.’”
Another SC participant indicated, “I had just fallen asleep. And then I had called (nurse 
practitioner) on Monday and she said it was OK, go ahead and take it Monday.”
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Communication with providers and coordinators was vital, not only for the provision of 
informational support about safe dosing, but also for the provision of emotional support to 
alleviate anxiety when they did not dose properly. The level of fear and need for emotional 
support is eloquently exemplified by the following utterance: “One day I didn’t take mine 
and I was scared to death. And I called (nurse practitioner) and I told her and she said don’t 
worry about it, just take it within 24 hours of that time that I missed. And that scared me to 
death… I mean it could make you have a nervous breakdown or stress level go up.” Thus, 
the patient-provider relationship provided multiple mechanisms by which improvements in 
patient adherence could be obtained: (a) as a social motivator that provided an external 
commitment to adhere; (b) by providing practical informational support in what “to do”; and 
(c) by alleviating patients’ anxiety about missing doses through emotional support.
Barriers to Antiviral Treatment Adherence
Study participants reported many different barriers to taking their medicines as prescribed 
and these barriers did not differ significantly between SC and CT participants. They 
generally talked about factors that contributed both to skipping doses altogether and to 
taking doses late, without distinguishing between the two; therefore, we present data on 
barriers to both types together. Most of the barriers described were logistical and led 
participants to miss or delay medication unintentionally. A few participants, however also 
discussed how side effects, most often nausea, led them to intentionally avoid taking 
medication (RBV tablets).
The most frequently described barrier to taking medications was getting busy or having a 
change in one’s daily routine (N=9). One man reported that taking a phone call distracted 
him from taking a dose: “I got busy! Phone calls…. The phone is ringing a lot.” Another 
participant found that his daily responsibilities taking care of his children sometimes led him 
to take doses later than scheduled: “Just, you know, life gets in the way. So, you know, 
getting the kids ready for school or getting the kids ready for bed. Just familial type stuff can 
get in the way of taking the medication.” Both work and leisure activities were listed as 
other examples of how getting busy can lead to missed or delayed doses. One woman 
reported: “When you get too busy or you’re out having fun or if you’re having fun, yeah, and 
time catches up with you;” another man described, “I get involved in work and then a 
couple hours pass on by. So I’ve got to stop and take my meds.”
Participants also described that getting busy affected their adherence indirectly by altering 
their eating schedule (N=6). One man described, “I remember one time I didn’t eat till like, 
like I missed breakfast. I was trying to get a bunch of stuff done. And I kept putting off 
breakfast and I didn’t eat. And then before I realized it, it was like 3:00 and then I figured 
‘well, I’ll make sure I take it at 10:00’.” Some participants reported particular problems 
adhering to a medication schedule because they do not eat at the same times every day; as 
one described, “One of my problems is I don’t eat every day at the same time. If I ate every 
day at the same time then it would be easy to remember.” Another man said that poor access 
to food sometimes kept him from taking a dose.
Getting busy and changes in daily routine got in the way of dose-taking particularly when 
they involved being away from home without medicines (N=6). One participant predicted 
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that if she ever did miss a medication it would happen if she was away from home: “That I 
got busy doing something away from the house because I don’t carry them with me.” Other 
participants recounted delaying or missing doses due to not bringing medications with them 
to work, out to eat, and on a trip out of town. A specific challenge of taking medications 
away from home is the time-consuming nature of taking these particular medication 
regimens. One participant illustrated how the “ritual” required for taking hepatitis C 
medications is difficult to slip into an altered schedule: “Well, I guess traveling or being, you 
know, not set in your home environment…. I was concerned about my medicines and, you 
know, someone else’s schedule and then getting back to my bag of medication and to - - 
even though I don’t like rituals, it turns into one. I just want to be able to pop one and go. 
But, no, you have to get them out of the packaging and do your diary and so it turns into a 
little ritual that you need some time to count, make sure you get it and don’t just think you 
did it and come back later and there they are, still there. ‘Whoops. I thought I took those,’ 
which has happened; not a long length of time but I said ‘I thought I’d popped them but 
there they are right there’.” Another man said that the large amount of medication supplies 
made it unlikely that he would take them with him outside of the home: “And then if you’re 
out or whatever, I mean you’re not going to carry this big week’s supply thing around, you 
know.”
Another salient barrier to taking medicines participants discussed was sleep. Participants 
reported both sleeping through morning doses and falling asleep (often watching television) 
before taking scheduled nighttime doses (N=7). One woman reported missing doses due to 
falling asleep prior to her evening dose: “And I’ve only forgotten to do it maybe three times. 
I actually fell asleep in the evening. Woke up a couple hours later and remembered to take 
it. And I just this past, last week, fell asleep and got up and went to bed. I forgot to take it at 
all. And that’s the only time that’s happened so far.”
A few patients intentionally skipping doses due to side effects, most notably nausea. 
Another problematic side effect mentioned by one participant was short-term memory loss, 
which made it difficult to remember to take doses; he described using a pill counter to help 
keep track of his doses: “I’d look at [the pill counter] and even if I knew I’d taken ‘em 
‘cause this stuff will give you like short-term memory loss big-time. Big time. You go to the 
kitchen. ‘What the hell am I doing here?’ I mean that’s not uncommon. You walk in the 
kitchen and it’s like you’re suddenly senile, you know?”
Although he did not admit to missing or delaying doses, one CT participant spoke in-depth 
about the burden of taking HCV medications, which could represent a negative attitude as a 
barrier to medication adherence and persistence:
“You’ll get tired of it. You’ll get overwhelmed by it all the time. ‘I just took it. I’ve 
got to do it again.’ And some people, if they’re ready to forget, they’ll do it on 
purpose. I could see where, OK, ‘God, I forgot. What are you going to do? Kill 
me?’” … “[the pills would] get stuck in my throat”, “there seems to be a lot of 
them, a lot of pills and it gets to be a bigger and bigger job sometimes”, and 
“mentally, you know, gets a little old.” Although this theme was not mentioned by 
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other participants, it emerged strongly from this individual and may represent 
others’ experiences.
Additional reasons for missing doses that were probed included “feeling too good,” “being 
overwhelmed,” or “depressed” but none were endorsed. Additionally, no significant group 
differences were found for gender or history of depression. Notably, no major differences 
between SC and CT participants, except where indicated above, were identified, suggesting 
that the dose-timing errors, facilitators and barriers identified here were ubiquitous across 
different patient characteristics and various antiviral regimens.
DISCUSSION
Adherence to HCV treatment plays a critical role in achieving a sustained virological 
response and when optimized may substantially improve health outcomes at the individual 
and public health level. The current study expands upon the handful of quantitative HCV 
adherence studies that exist, by capturing qualitatively, patients’ experiences with these 
treatment regimens, a perspective overlooked in the HCV adherence literature until now. 
Several of our findings are consistent with previous adherence studies conducted in other 
medical or treatment populations, such as HIV (15). Other findings, however, were new, 
perhaps unique to HCV treatment, and are worthy of further exploration, as described 
below. Additionally, while we did not apply a theory-guided approach during interview 
guide development, we recognized post-hoc that many of our findings, particularly factors 
which facilitate adherence, fit exceptionally well within an a priori conceptual model known 
as the Information-Motivation-Behavior Skills (IMB) Model of Adherence (16) that may 
serve as a useful framework for HCV adherence researchers, as well as clinicians preparing 
their patients for treatment and supporting adherence efforts during treatment.
The IMB model of adherence is based upon an analysis and integration of social and health 
psychology theories and supported by twenty years of research (16), with various health 
behaviors, most commonly HIV antiretroviral adherence. The IMB model posits that three 
fundamental determinants drive adherent behavior: 1) information/knowledge; 2) personal 
and social motivation; and 3) behavioral skills(16). Accordingly, patients who are well-
informed about treatment, have internal and external motivations to adhere, and possess 
effective behavioral skills will be more likely to adhere to treatment.
Consistent with the IMB model and previous studies in HIV, HCV patients in the current 
study described knowledge and information about the important role of medication 
adherence, as being critical to adherence. Patients also described both social and personal 
motivators as key to adherence. Social motivators came in the form of an external 
commitment to a research trial, having a strong rapport built with the research coordinator/
medical provider, or simply feeling grateful and “having the opportunity to undergo 
treatment.” These findings are consistent with the IMB model and a growing body of work 
demonstrating that the patient-provider relationship and patients’ perception of provider 
support are critical to medication adherence (16–19). For HCV patients, the provider-patient 
relationship seems to be a critical mediator or mechanism of treatment engagement, 
including adherence (18, 20). In the current study, we found that through various 
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mechanisms of social support, the patient-provider/coordinator relationship served multiple 
purposes: it motivated patients; provided tangible informational support in the event of 
missed doses; and helped patients manage dosing-related anxiety after “messing up.” 
Interestingly the importance of the patient-provider relationship to adherence may have 
trumped the importance of family support, as evidenced by more references to the 
importance of the patient-provider relationship than to family relationships. Also consistent 
with the IMB model, participants in this study described experiences they had shoring up 
their personal motivation to adhere, such as developing an internal sense of determination 
and resolve, using helpful, cheerleading-like self-statements, and future-oriented optimistic 
thoughts about the long-term positive consequences they associated with being cured. These 
were all important cognitive motivators patients believed fueled their adherence and 
persistence. No major differences were found in types of motivators for patients treated in 
SC or CTs or those with and without cirrhosis. An exception to this was that patients without 
cirrhosis, compared to those with cirrhosis, made more utterances reflecting motivation from 
an internal locus of control (i.e., the belief that their behaviors/actions controlled events in 
their lives). Finally, behavioral skills were essential to facilitating adherence such as 
documented in studies of HIV adherence (15, 21). The most common behaviors were 
establishing weekly dosing routines, which were even described as “ritualistic.” The routine 
sometimes occurred after some trial and error to configure dosing around anticipated side 
effects, occupational and family duties, meal time, and sleep habits. Patients also described 
ways in minimize the impact of side effects and reduce the unpleasantness of the medication 
dosing experience (e.g., how to carefully administer the injection or counteract the bitterness 
of pills with candy or chocolate). Taken together, these findings provide strong support for 
the three main determinants/facilitators of the IMB model (information, motivation, 
behavioral skills) and offer a useful conceptual framework in which to study, and potentially 
intervene upon, HCV treatment adherence.
With regard to barriers to adherence, patients cited numerous hindrances that have been 
reported elsewhere, such as in the HIV adherence literature: changes in routine, being too 
busy, sleeping through dosing times, as well as short-term memory issues, pill burden, 
competing work and family responsibilities (15). Only a few patients described purposefully 
skipping doses due to side effects, which may be more common in other treatment 
populations (22). Patients did not endorse missing doses due to feeling good, feeling 
depressed or overwhelmed, however, many indicated that treatment was overwhelming and 
interfered with their daily lives. Finally, pairing medication-taking with meal time had its 
advantages and disadvantages: meals were a good environmental cue to prompt medication 
taking as long as the patients always ate meals on schedule. However, if they became too 
busy to eat, then medication-taking was also delayed.
Two other themes that emerged are noteworthy because they provide highly useful 
information that clinicians can use to facilitate communication about adherence with their 
patients: (a) delays in dosing and (b) adherence-related anxiety. First, participants did not 
consider delays in dosing to be the same as “missed doses,” highlighting the need to be 
cognizant of how adherence is queried in the clinical setting. Patients did not endorse 
missing doses when asked in a routine manner (e.g., “Did you miss any doses?”), but when 
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probed further about delays in dosing, patients then acknowledged times when dosing 
occurred a few to several hours later than they originally intended, and this applied to 
patients treated in clinical trials and in standard of care. Patients who had previously 
undergone HCV treatment demonstrated fewer dose-timing errors (33%) than patients on 
their first course of treatment (60%), suggesting that patients with prior experience with 
HCV treatment may have fewer dose-timing errors and greater medication adherence during 
a subsequent course of treatment. We noted a few instances where patients “doubled up” on 
their oral medications when they forgot the earlier dose. Delayed dosing may not be as 
critical when there is a 12-hour or 24-hour window to dose; however, when a routine is not 
implemented and patients take their medications at any time point during the day, there is 
more room for forgetting to take them. Also, if oral regimens in the future require stricter 
dosing windows, such delays may have an impact on adherence, drug efficacy, development 
of mutant viral strains, and treatment success (22–24) Clinically, this finding highlights the 
importance of patient-provider communication style, suggesting that subtle differences in 
questioning style may elicit dramatically different patient self-reports (22). Querying about 
differences between intended and actual dosing times, such as, “You’ve told me that you try 
to take your medications at 8a.m. and 6p.m. What gets in the way of taking them right at 8 
or 6 where you might find that you take them several hours later?” may elicit more useful 
information about delayed dosing that can be used to coach patients about behavioral skills. 
Use of “implementation intentions” can help patients determine exactly when, where and 
how to dose medications as prescribed in an environmentally-cued, ritualistic manner (25). 
Finally, patients described a “trial and error” period in the first few weeks of treatment as 
they attempted to develop a dosing routine. Clinicians may consider recommending a “trial 
and error” period prior to starting HCV treatment using fake medicines (e.g., jellybeans) so 
that patients can work through these logistical issues before starting the real regimen, 
thereby reducing dose-timing errors early in treatment that could impede achieving rapid 
virological response.
A second somewhat unexpected theme was the level of anxiety and fear both SC and CT 
patients reported regarding adherence to the HCV regimen. “Adherence-related anxiety” is 
not a well-described phenomenon in the adherence literature and warrants consideration. 
First, adherence-related anxiety is not described as a specific determinant of adherent 
behaviors in the IMB model, although theoretically, it could be categorized as a moderator 
such as general mental health (16). It is possible that the adherence-related anxiety taps into 
pre-existing anxiety but it will be important to make this distinction. Second, it may be that 
adherence-related anxiety is somewhat unique to HCV treatment due to a variety of factors 
but including: a) the tremendous perseverance it takes to become eligible and start HCV 
treatment; b) the perceived benefit of HCV treatment (i.e., “cure”); and c) the relatively 
intense but time-limited regimen. Third, consistent with the Yerkes-Dodson theory, it may 
be that a moderate level of anxiety is optimal for best adherence performance (26). When 
anxiety is too low, individuals may be complacent; when too high, it may interfere with 
performance. Thus, one aspect of helping patients’ achieve optimal adherence may involve 
helping them to maintain a moderate level of anxiety that keeps them vigilant and on-task, 
but not overly fearful.
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Limitations of this study are the small sample size, heterogeneity of patient characteristics, 
and inability to statistically analyze qualitative data, though this was not the intent of this 
study. Also, the findings from this study may not be representative of dissimilar HCV 
patients or clinical settings being treated elsewhere and may not apply to other patient 
populations undergoing medical treatment. Conversely, findings from other adherence 
studies may not apply to patients undergoing HCV treatment. Patients with HCV often have 
to overcome significant personal, social, financial, and structural obstacles in order to 
embark on HCV treatment; therefore, patients who actually undergo HCV treatment such as 
these in standard practice and especially clinical trials may represent a relatively motivated 
group of individuals likely to adhere. Those that ultimately chose to undergo treatment may 
be markedly more motivated compared to individuals from the community who are 
diagnosed but not invested in treatment. Additionally, HCV treatment is intense, time-
limited, and can be wrought with side effects, yet curative; thus, it represents a rather unique 
setting in which to study medication adherence. More systematic research is clearly 
warranted. Future directions for research may include large quantitative studies to confirm 
these findings, studies to prospectively examine whether the IMB model is a good fit to 
capture determinants of HCV adherence and exploration of adherence-related anxiety and 
whether it has a curvilinear relationship with adherence.
This qualitative study is an important first step towards understanding patient factors that 
should be addressed to improve HCV treatment adherence. Before adherence interventions 
for HCV can be developed, more research is needed to understand better the prevalence of 
determinants and moderators of adherence, and application of theoretical models such as the 
IMB will almost certainly prove useful. The data from this small study also provide 
clinicians with a glimpse into the needs of patients during HCV treatment and provide 
insight into ways in which we can improve clinical care by addressing patient knowledge, 
motivation, and behavioral skills.
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TABLE 1
INTERVIEW GUIDE
Topic Area Specific Questions Asked Probes
1 Patients’ General 
Experience with HCV 
Treatment
We would like to hear from you about your 
experiences with undergoing HCV treatment
How do you feel about taking these medications?
How do you think these medications are affecting 
your health?
What is the hardest thing about being on this 
treatment?
What other things has the treatment affected in your 
life?
2 Side Effects/Coping Tell me about what kind of side effects you have 
been experiencing?
What helps with dealing with those side effects?
Tell me about any experiences with irritability… 
nausea….insomnia…feeling tired…being achy?
What do you do to cope with side effects?
What do you think or tell yourself to help deal with 
side effects?
How have the side effects affected your role at 
work, or at home?
3 Depression/Coping What was your mood like before you started Hep 
C treatment?
What has your mood been like since starting Hep 
C treatment?
Do you think there is a direct link between the 
Hep C medications, and your mood?
When you are feeling down/irritable/nervous, 
what helps you the most?
Tell me more about that…
What do you think or tell yourself to help deal with 
your mood?
4 Other Life Interference In addition to side effects, what other things have 
been difficult for you during treatment?
What things have been good for you during 
treatment?
5 Social Support Tell me about the support you have had from 
friends, family, or other groups to which you 
belong?
Are there other types of support that you are not 
getting during treatment, that you think would be 
helpful for you?






6 Facilitators to Medication-
Taking Adherence 
Patients Understanding of 
Adherence
Tell me about the process of taking your HCV 
medications?
What do you do think helps you take your 
medications as prescribed?
How important do you think it is to take your 
medications exactly like your doctor told you to?
7 Barriers to Medication-
Taking Adherence
What gets in the way of you taking your 
medications?
Have you EVER missed taken your medications 
because …
You felt too good
You fell asleep or slept through dose time
You simply forgot
You had a change in your daily routine
You got busy with other things
You felt too sick/ill
You felt depressed/overwhelmed
Do you think you could benefit from talking about 
other ways to help take your medications
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TABLE 2
PATIENT CHARACTERISTICS
Patient Characteristics N %
Gender
 Male 14 66.7
 Female 7 33.3
Ethnicity
 Caucasian 20 95.2
 African-American 1 4.8
Marital Status
 Single 5 23.8
 Married or Partnered 11 52.4
 Divorced 4 19.0
 Widowed 1 4.8
Education Status
 < High School Diploma 4 19.0
 > High School Diploma 17 81.0
Estimated Annual Household Income
 <$40,000 9 42.9
 $41,000 to $60,000 2 9.5
 $61,000 to $100,000 5 23.8
 >$100,000 2 9.5
 Refused 3 14.3
Employment Status
 Full-Time or Part-Time 12 57.1
 Unemployed 4 19.0
 Disabled 1 4.8
 Retired 2 9.5
 Homemaker 2 9.5
Insurance Status
 Private 13 61.9
 Public Medicaid or Medicare 1 4.8
 No Insurance/Self-Pay 3 14.3
 Supplemental Hospital Support 4 19.0
Liver Disease Status
 Cirrhosis 9 43%
 No Cirrhosis 12 57%
Treatment Status
 Treatment Naive 15 71%
 Treatment Experienced 6 29%
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